Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neurosurgical Procedures × Clear all
NCT00659334 2022-12-21

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

OHSU Knight Cancer Institute

Phase 2 Terminated
116 enrolled 12 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡